Related Experiment Videos
Ciprofloxacin-associated hemolytic-uremic syndrome
David S Allan1, Cheryl M Thompson, Robert M Barr
1University of Western Ontario, London, Canada.
The Annals of Pharmacotherapy
|May 23, 2002
Summary
This case report details the first instance of hemolytic-uremic syndrome (HUS) linked to ciprofloxacin. Early detection and drug withdrawal are crucial for patient recovery from this adverse drug reaction.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are rare but serious conditions.
- These syndromes can be associated with various factors including cancer, chemotherapy, and certain medications.
Observation:
- A 53-year-old male undergoing chemotherapy for acute lymphoblastic leukemia developed HUS.
- Symptoms included microangiopathic hemolytic anemia, renal failure, and thrombocytopenia after receiving oral ciprofloxacin.
Findings:
- This case represents the first reported instance of HUS associated with ciprofloxacin use.
- The adverse drug reaction was assessed as possibly causally related using the Naranjo probability scale.
Implications:
- Ciprofloxacin may be an underrecognized cause of HUS.
- Prompt recognition, cessation of the drug, and appropriate treatment are vital for managing ciprofloxacin-induced HUS.